Login Register Cart 0
Generic placeholder image

Current Drug Research Reviews

Editor-in-Chief

ISSN (Print): 2589-9775
ISSN (Online): 2589-9783

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Systematic Review Article

Systematic Review and Meta-analysis of the Relationship Between Proton Pump Inhibitors and Esophageal Adenocarcinoma

Author(s): Mohammad Darvishi, Saeid Soureshjan-Heidari* and Matin Bidares

Volume 15, Issue 3, 2023

Published on: 27 February, 2023

Page: [262 - 271] Pages: 10

DOI: 10.2174/2589977515666230112165525

Price: $65

conference banner
Abstract

Introduction and Aim: Esophageal adenocarcinoma (EAC) mortality continues to increase across the world. This meta-analysis was aimed to investigate the relationship between proton pump inhibitors (PPIs) and the risk of EAC.

Methods: This meta-analysis was done as per the PRISMA checklist using relevant keywords. To this end, an extensive search was done on 29/6/2022 in EMBASE, Web of Science (ISI), PubMed, and Scopus. In this study, 95% confidence interval (CI) and standardized mean difference (SMD) were used to estimate the overall effect size. Analysis of the odds ratio (OR) for EAC was done using a random effects model.

Results: A total of 20 studies were included in the review. Compared to the group that received PPIs, the OR of EAC in the recipients of the PPIs group was obtained at 0.67 (95% CI = 0.39-1.29, P = 0.240). The meta-regression, including year, follow-up time, study design, sample size, quality of the study, study period, and geographical location, demonstrated no source of heterogeneity (P > 0.10).

Conclusion: No significant relationship was found between PPIs use and the risk of EAC. Accordingly, PPIs do not have a protective or risk factor effect on EAC.

« Previous Next »
[1]
Abbas G, Krasna M. Overview of esophageal cancer. Ann Cardiothorac Surg 2017; 6(2): 131-6.
[http://dx.doi.org/10.21037/acs.2017.03.03] [PMID: 28447001]
[2]
Grille VJ, Campbell S, Gibbs JF, Bauer TL. Esophageal cancer: the rise of adenocarcinoma over squamous cell carcinoma in the Asian belt. J Gastrointest Oncol 2021; 12 (Suppl. 2): S339-49.
[http://dx.doi.org/10.21037/jgo-2019-gi-08] [PMID: 34422398]
[3]
PDQ. Esophageal Cancer Treatment (Adult) (PDQ®). Health Professional Version. PDQ Cancer Information Summaries 2002.
[4]
de Jonge PJF, Steyerberg EW, Kuipers EJ, et al. Risk factors for the development of esophageal adenocarcinoma in Barrett’s esophagus. Am J Gastroenterol 2006; 101(7): 1421-9.
[http://dx.doi.org/10.1111/j.1572-0241.2006.00626.x] [PMID: 16863542]
[5]
Yibirin M, De Oliveira D, Valera R, Plitt AE, Lutgen S. Adverse effects associated with proton pump inhibitor use. Cureus 2021; 13(1): e12759.
[http://dx.doi.org/10.7759/cureus.12759] [PMID: 33614352]
[6]
Islam MM, Poly TN, Walther BA, et al. Adverse outcomes of long-term use of proton pump inhibitors: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2018; 30(12): 1395-405.
[http://dx.doi.org/10.1097/MEG.0000000000001198] [PMID: 30028775]
[7]
Singh S, Garg SK, Singh PP, Iyer PG, El-Serag HB. Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with Barrett’s oesophagus: a systematic review and meta-analysis. Gut 2014; 63(8): 1229-37.
[http://dx.doi.org/10.1136/gutjnl-2013-305997] [PMID: 24221456]
[8]
Chen YH, Yu HC, Lin KH, Lin HS, Hsu PI. Prevalence and risk factors for Barrett’s esophagus in Taiwan. World J Gastroenterol 2019; 25(25): 3231-41.
[http://dx.doi.org/10.3748/wjg.v25.i25.3231] [PMID: 31333314]
[9]
Hu Q, Sun TT, Hong J, Fang JY, Xiong H, Meltzer SJ. Proton pump inhibitors do not reduce the risk of esophageal adenocarcinoma in patients with barrett’s esophagus: A systematic review and meta-analysis. PLoS One 2017; 12(1): e0169691.
[http://dx.doi.org/10.1371/journal.pone.0169691] [PMID: 28072858]
[10]
Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa: Ottawa Hospital Research Institute 2011; pp. 1-12.
[11]
Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Ann Intern Med 2001; 135(11): 982-9.
[http://dx.doi.org/10.7326/0003-4819-135-11-200112040-00010] [PMID: 11730399]
[12]
Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials 1996; 17(1): 1-12.
[http://dx.doi.org/10.1016/0197-2456(95)00134-4] [PMID: 8721797]
[13]
Liu P. Medications, sex hormones and reproductive factors in relation to gastro-oesophageal cancer risk and survival: Queen's University Belfast 2021.
[14]
Hippisley-Cox J, Mei XW, San Tan P, et al. Chronic acid-suppressant use and risk of Oesophageal cancer: protocol for a longitudinal study using a large population based cohort. medRxiv 2021; 2021; 21251618.
[http://dx.doi.org/10.1101/2021.02.15.21251618]
[15]
Fioretti F, Tavani A, La Vecchia C, Franceschi S. Histamine-2-receptor antagonists and oesophageal cancer. Eur J Cancer Prev 1997; 6(2): 143-6.
[PMID: 9237063]
[16]
Altawil J, Irwin B, Jinjuvadia R, et al. Can progression to dysplasia in barrett’s esophagus be prevented by proton pump inhibitors? J Am College Gastroenterol 2011; 106: S31.
[17]
Raoul JL, Guérin-Charbonnel C, Edeline J, Simmet V, Gilabert M, Frenel JS. Prevalence of proton pump inhibitor use among patients with cancer. JAMA Netw Open 2021; 4(6): e2113739.
[http://dx.doi.org/10.1001/jamanetworkopen.2021.13739] [PMID: 34132796]
[18]
Hillman LC, Chiragakis L, Shadbolt B, Kaye GL, Clarke AC. Effect of proton pump inhibitors on markers of risk for high-grade dysplasia and oesophageal cancer in Barrett’s oesophagus. Aliment Pharmacol Ther 2008; 27(4): 321-6.
[http://dx.doi.org/10.1111/j.1365-2036.2007.03579.x] [PMID: 18047565]
[19]
Duan L, Wu AH, Sullivan-Halley J, Bernstein L. Antacid drug use and risk of esophageal and gastric adenocarcinomas in Los Angeles County. Cancer Epidemiol Biomarkers Prev 2009; 18(2): 526-33.
[http://dx.doi.org/10.1158/1055-9965.EPI-08-0764] [PMID: 19190141]
[20]
Alexandropoulou K, van Vlymen J, Reid F, Poullis A, Kang JY. Temporal trends of Barrett’s oesophagus and gastro-oesophageal reflux and related oesophageal cancer over a 10-year period in England and Wales and associated proton pump inhibitor and H2RA prescriptions. Eur J Gastroenterol Hepatol 2013; 25(1): 15-21.
[http://dx.doi.org/10.1097/MEG.0b013e3283595086] [PMID: 23022985]
[21]
Brusselaers N, Lagergren J, Engstrand L. Duration of use of proton pump inhibitors and the risk of gastric and oesophageal cancer. Cancer Epidemiol 2019; 2019: 62101585.
[http://dx.doi.org/10.1016/j.canep.2019.101585] [PMID: 31445426]
[22]
Chow WH, Finkle WD, McLaughlin JK, Frankl H, Ziel HK, Fraumeni JF Jr. The relation of gastroesophageal reflux disease and its treatment to adenocarcinomas of the esophagus and gastric cardia. JAMA 1995; 274(6): 474-7.
[http://dx.doi.org/10.1001/jama.1995.03530060048032] [PMID: 7629956]
[23]
Gao J, Ma S, Xu S, Chen M. The association of long-term use of proton pump inhibitors and histamine H2 receptor antagonists with clinical complications in patients with severe sepsis. Dis Markers 2022; 2022: 4093595.
[http://dx.doi.org/10.1155/2022/4093595] [PMID: 35801003]
[24]
Habel LA, Levin TR, Friedman GD. Cimetidine use and risk of breast, prostate, and other cancers. Pharmacoepidemiol Drug Saf 2000; 9(2): 149-55.
[http://dx.doi.org/10.1002/(SICI)1099-1557(200003/04)9:2<149:AID-PDS481>3.0.CO;2-1] [PMID: 19025815]
[25]
Suleiman UL, Harrison M, Britton A, McPherson K, Bates T. H2-receptor antagonists may increase the risk of cardio-oesophageal adenocarcinoma. Eur J Cancer Prev 2000; 9(3): 185-92.
[http://dx.doi.org/10.1097/00008469-200006000-00006] [PMID: 10954258]
[26]
Arai J, Niikura R, Hayakawa Y, et al. Chemoprevention of oesophageal squamous-cell carcinoma and adenocarcinoma: A multicentre retrospective cohort study. Digestion 2022; 103(3): 192-204.
[http://dx.doi.org/10.1159/000520924] [PMID: 34929693]
[27]
Brusselaers N, Engstrand L, Lagergren J. Maintenance proton pump inhibition therapy and risk of oesophageal cancer. Cancer Epidemiol 2018; 53: 172-7.
[http://dx.doi.org/10.1016/j.canep.2018.02.004] [PMID: 29477057]
[28]
Choi HG, Lee HK, Kang HS, et al. Possible association between the use of proton pump inhibitors and H2 Receptor Antagonists, and Esophageal Cancer: A Nested Case–Control Study Using a Korean National Health Screening Cohort. Pharmaceuticals (Basel) 2022; 15(5): 517.
[http://dx.doi.org/10.3390/ph15050517] [PMID: 35631344]
[29]
Cooper BT, Chapman W, Neumann CS, Gearty JC. Continuous treatment of Barrett’s oesophagus patients with proton pump inhibitors up to 13 years: observations on regression and cancer incidence. Aliment Pharmacol Ther 2006; 23(6): 727-33.
[http://dx.doi.org/10.1111/j.1365-2036.2006.02825.x] [PMID: 16556174]
[30]
Crane SJ, Locke GR III, Harmsen WS, et al. Subsite-specific risk factors for esophageal and gastric adenocarcinoma. Am J Gastroenterol 2007; 102(8): 1596-602.
[http://dx.doi.org/10.1111/j.1572-0241.2007.01234.x] [PMID: 17459024]
[31]
Gaddam S, Thota PN, Vennalaganti P, et al. 710 Proton pump inhibitor use but not statin use is associated with decreased risk for high-grade dysplasia and esophageal adenocarcinoma in patients with barrett’s esophagus: results from a large, multicenter cohort study. Gastroenterology 2014; 146(5): S-123.
[http://dx.doi.org/10.1016/S0016-5085(14)60442-X]
[32]
Rodriguez L A G, Lagergren J, Lindblad M. Gastric acid suppression and risk of oesophageal and gastric adenocarcinoma: a nested case control study in the UK. Gut 2006; 55(11): 1538-44.
[http://dx.doi.org/10.1136/gut.2005.086579] [PMID: 16785284]
[33]
Hillman LC, Chiragakis L, Kaye GL, Clarke AC, Shadbolt B. Proton‐pump inhibitor therapy and the development of dysplasia in patients with Barrett’s oesophagus. Med J Aust 2004; 180(8): 387-91.
[http://dx.doi.org/10.5694/j.1326-5377.2004.tb05991.x] [PMID: 15089728]
[34]
Hvid-Jensen F, Pedersen L, Funch-Jensen P, Drewes AM. Proton pump inhibitor use may not prevent high-grade dysplasia and oesophageal adenocarcinoma in Barrett’s oesophagus: a nationwide study of 9883 patients. Aliment Pharmacol Ther 2014; 39(9): 984-91.
[http://dx.doi.org/10.1111/apt.12693] [PMID: 24617286]
[35]
Jankowski JAZ, de Caestecker J, Love SB, et al. Esomeprazole and aspirin in Barrett’s oesophagus (AspECT): a randomised factorial trial. Lancet 2018; 392(10145): 400-8.
[http://dx.doi.org/10.1016/S0140-6736(18)31388-6] [PMID: 30057104]
[36]
Jung KW, Talley NJ, Romero Y, et al. Epidemiology and natural history of intestinal metaplasia of the gastroesophageal junction and Barrett’s esophagus: a population-based study. Am J Gastroenterol 2011; 106(8): 1447-55.
[http://dx.doi.org/10.1038/ajg.2011.130] [PMID: 21483461]
[37]
Kastelein F, Spaander MCW, Steyerberg EW, et al. Proton pump inhibitors reduce the risk of neoplastic progression in patients with Bar-rett’s esophagus. Clin Gastroenterol Hepatol 2013; 11(4): 382-8.
[http://dx.doi.org/10.1016/j.cgh.2012.11.014] [PMID: 23200977]
[38]
Krishnamoorthi R, Borah B, Heien H, Das A, Chak A, Iyer PG. Rates and predictors of progression to esophageal carcinoma in a large population-based Barrett’s esophagus cohort. Gastrointest Endosc 2016; 84(1): 40-46.e7.
[http://dx.doi.org/10.1016/j.gie.2015.12.036] [PMID: 26772891]
[39]
Loomans-Kropp HA, Chaloux M, Richmond E, Umar A. association of common use pharmaceuticals in reducing risk of esophageal adenocarcinoma: A SEER-medicare analysis. Cancer Prev Res (Phila) 2021; 14(2): 195-204.
[http://dx.doi.org/10.1158/1940-6207.CAPR-20-0274] [PMID: 32998939]
[40]
Masclee GMC, Coloma PM, Spaander MCW, Kuipers EJ, Sturkenboom MCJM. NSAIDs, statins, low-dose aspirin and PPIs, and the risk of oesophageal adenocarcinoma among patients with Barrett’s oesophagus: a population-based case-control study. BMJ Open 2015; 5(1): e006640.
[http://dx.doi.org/10.1136/bmjopen-2014-006640] [PMID: 25633286]
[41]
Nguyen DM, El-Serag HB, Henderson L, Stein D, Bhattacharyya A, Sampliner RE. Medication usage and the risk of neoplasia in patients with Barrett’s esophagus. Clin Gastroenterol Hepatol 2009; 7(12): 1299-304.
[http://dx.doi.org/10.1016/j.cgh.2009.06.001] [PMID: 19523538]
[42]
Nguyen DM, Richardson P, El-Serag HB. Medications (NSAIDs, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett’s esophagus. Gastroenterology 2010; 138(7): 2260-6.
[http://dx.doi.org/10.1053/j.gastro.2010.02.045] [PMID: 20188100]
[43]
Tan MC, El-Serag HB, Yu X, Thrift AP. Acid suppression medications reduce risk of oesophageal adenocarcinoma in Barrett’s oesophagus: a nested case-control study in US male veterans. Aliment Pharmacol Ther 2018; 48(4): 469-77.
[http://dx.doi.org/10.1111/apt.14895] [PMID: 29956826]
[44]
Thota PN, Hajifathalian K, Benjamin T, Runkana A, Lopez R, Sanaka MR. Lack of incremental effect of histamine receptor antagonists over proton pump inhibitors on the risk of neoplastic progression in patients with Barrett’s esophagus: a cohort study. J Dig Dis 2017; 18(3): 143-50.
[http://dx.doi.org/10.1111/1751-2980.12457] [PMID: 28188977]
[45]
van Aert RCM, Wicherts JM, van Assen MALM. Publication bias examined in meta-analyses from psychology and medicine: A meta-meta-analysis. PLoS One 2019; 14(4): e0215052.
[http://dx.doi.org/10.1371/journal.pone.0215052] [PMID: 30978228]
[46]
Lin L, Chu H. Quantifying publication bias in meta-analysis. Biometrics 2018; 74(3): 785-94.
[http://dx.doi.org/10.1111/biom.12817] [PMID: 29141096]
[47]
Zeng R, Cheng Y, Luo D, et al. Comprehensive analysis of proton pump inhibitors and risk of digestive tract cancers. Eur J Cancer 2021; 156: 190-201.
[http://dx.doi.org/10.1016/j.ejca.2021.07.030] [PMID: 34481369]
[48]
Krishnamoorthi R, Singh S, Ragunathan K, et al. Factors associated with progression of Barrett’s esophagus: A systematic review and meta-analysis. clin gastroenterol hepatol 2018; 16(7): 1046-1055.e8.
[http://dx.doi.org/10.1016/j.cgh.2017.11.044] [PMID: 29199147]
[49]
Yang CS, Chen X, Tu S. Etiology and Prevention of Esophageal Cancer. Gastrointest Tumors 2016; 3(1): 3-16.
[http://dx.doi.org/10.1159/000443155] [PMID: 27722152]
[50]
Huang FL, Yu SJ. Esophageal cancer: Risk factors, genetic association, and treatment. Asian J Surg 2018; 41(3): 210-5.
[http://dx.doi.org/10.1016/j.asjsur.2016.10.005] [PMID: 27986415]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy